Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00471146
First received: May 7, 2007
Last updated: June 14, 2012
Last verified: June 2012
  Purpose

The purpose of this study is to determine whether investigational study drug, AG-013736, and gemcitabine are effective in the first-line treatment of advanced pancreatic cancer.


Condition Intervention Phase
Carcinoma, Pancreatic Ductal
Drug: AG-013736
Drug: Gemcitabine
Drug: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind Phase 3 Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine Plus Placebo For The First-Line Treatment Of Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer.

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Overall Survival (OS) [ Time Frame: Baseline until death or at least 1 year after the randomization of last participant ] [ Designated as safety issue: No ]
    Time in weeks from randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 7. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).


Secondary Outcome Measures:
  • Progression Free Survival (PFS) [ Time Frame: Baseline until disease progression or at least 1 year after the randomization of last participant ] [ Designated as safety issue: No ]
    Time in weeks from randomization to the first documentation of objective tumor progression or death due to any cause. PFS was calculated as = (first event date minus randomization date plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]), or from adverse event (AE) data (where the outcome was "Death").

  • Percentage of Participants With Objective Response (OR) [ Time Frame: Baseline, every 8 weeks until tumor progression or death ] [ Designated as safety issue: No ]
    Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.

  • Duration of Response (DR) [ Time Frame: Baseline until death or at least 1 year after the randomization of last participant ] [ Designated as safety issue: No ]
    Time in weeks from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 7.

  • Change From Baseline in European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score [ Time Frame: Baseline, Day 1 (D1) of each cycle (C2-C13) up to 28 days after the last dose (follow-up) or early withdrawal ] [ Designated as safety issue: No ]
    EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status (GHS), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea, and financial difficulties). Most questions used 4- point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores averaged, transformed to 0- 100 scale; higher score=better level of functioning or greater degree of symptoms. Change from baseline=Cycle/Day score minus baseline score.

  • Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Pancreatic 26 (EORTC QLQ- PAN26) Score [ Time Frame: Baseline, Day 1 (D1) of each cycle (C2-C13) up to 28 days after the last dose (follow-up) or early withdrawal ] [ Designated as safety issue: No ]
    QLQ-PAN26 consists of 26 questions (Qs) relating to disease symptoms, treatment (Tx) side effects and emotional issues specific to pancreatic cancer (PC). Questions include on altered bowel habits, pain, dietary changes, disease and Tx-related symptoms and issues related to the emotional and social well-being of participants with PC. All 26 Qs are answered on 4-point Likert scale ranging from '1=not at all' to 4='very much' and subsequently transformed into scales that range from 0-100; higher scores= greater degree of symptoms or treatment side effects and emotional issues.

  • Change From Baseline Brief Pain Inventory-short Form (BPI-sf) Score [ Time Frame: Baseline, Day 1 (D1) of each cycle (C2-C13) up to 28 days after the last dose (follow-up) or early withdrawal ] [ Designated as safety issue: No ]
    BPI-sf is an 11-item self-report questionnaire that is designed to assess the severity and impact of pain on daily functions. BPI-sf are 4 questions that assess pain intensity (worst, least, average, right now) and 7 questions that assess impact of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life). Each question is answered on a scale ranging from 0 to 10; '0=No pain and 10=Pain as bad as you can imagine'. Measure can be scored by item, with lower scores being indicative of less pain or pain interference.

  • Change From Baseline in Euro QoL Questionnaire- 5 Dimension (EQ-5D) Health State Profile [ Time Frame: Baseline, Day 1 (D1) of each cycle (C2-C13) up to 28 days after the last dose (follow-up) or early withdrawal ] [ Designated as safety issue: No ]
    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (eg, "confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

  • Change From Baseline in Euro QoL Questionnaire- 5 Dimension (EQ-5D) VAS Score [ Time Frame: Baseline, Day 1 (D1) of each cycle (C2-C13) up to 28 days after the last dose (follow-up) or early withdrawal ] [ Designated as safety issue: No ]
    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.

  • Population Pharmacokinetic (PK) Analysis for Axitinib (AG-013736) [ Time Frame: Day 1 (pre-dose), Day 29, Day 57 and then every 8 weeks up to 23 months ] [ Designated as safety issue: No ]
    Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.


Enrollment: 630
Study Start Date: July 2007
Study Completion Date: November 2010
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: AG-013736
oral administration, starting dose 5 mg twice daily [BID] every day until unacceptable toxicity or tumor progression.
Drug: Gemcitabine
intravenous administration at 1,000 mg/m^2 day 1, day 8 and day 15 every 4 weeks (conventional dose) until unacceptable toxicity or tumor progression.
Active Comparator: B Drug: Gemcitabine
intravenous administration at 1,000 mg/m^2 day 1, day 8 and day 15 every 4 weeks (conventional dose) until unacceptable toxicity or tumor progression.
Drug: placebo
placebo

Detailed Description:

This study was prematurely discontinued for futility on 23 January 2009, based on a planned interim analysis by an independent Data Safety Monitoring Board (DSMB) that found no evidence of improvement in the primary endpoint (survival) in patients treated with axitinib and gemcitabine compared to gemcitabine alone. Enrollment on this study has been discontinued.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed, metastatic or locally-, advanced pancreatic adenocarcinoma not amenable to curative resection.
  • Adequate renal, hepatic and bone marrow function.
  • Performance status 0 or 1.

Exclusion Criteria:

  • Prior treatment with any systemic chemotherapy for metastatic disease.
  • Prior treatment with gemcitabine, AG-013736, or other vascular endothelial growth factor inhibitors.
  • Current or recent bleeding, thromboembolic event and or use of a thrombolytic agent.
  • Inability to take oral medication.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00471146

  Hide Study Locations
Locations
United States, California
Pfizer Investigational Site
Antioch, California, United States, 94531
Pfizer Investigational Site
Corona, California, United States, 92878
Pfizer Investigational Site
Glendora, California, United States, 91741
Pfizer Investigational Site
La Jolla, California, United States, 92037
Pfizer Investigational Site
La Jolla, California, United States, 92093
Pfizer Investigational Site
LaVerne, California, United States, 91750
Pfizer Investigational Site
Pamona, California, United States, 91105
Pfizer Investigational Site
Pasadena, California, United States, 91105
Pfizer Investigational Site
Pleasent Hill, California, United States, 94523
Pfizer Investigational Site
Pomona, California, United States, 91767
Pfizer Investigational Site
Rancho Cucamonga, California, United States, 91730
Pfizer Investigational Site
Rancho Mirage, California, United States, 92270
Pfizer Investigational Site
Redlands, California, United States, 92374
Pfizer Investigational Site
San Diego, California, United States, 92161
Pfizer Investigational Site
San Diego, California, United States, 92103
Pfizer Investigational Site
San Leandro, California, United States, 94578
Pfizer Investigational Site
West Covina, California, United States, 91790
United States, Florida
Pfizer Investigational Site
Hollywood, Florida, United States, 33021
Pfizer Investigational Site
Pembroke Pines, Florida, United States, 33028
Pfizer Investigational Site
Stuart, Florida, United States, 34994
Pfizer Investigational Site
Tampa, Florida, United States, 33612
United States, Georgia
Pfizer Investigational Site
Atlanta, Georgia, United States, 30309
Pfizer Investigational Site
Augusta, Georgia, United States, 30909
Pfizer Investigational Site
Augusta, Georgia, United States, 30901
United States, Idaho
Pfizer Investigational Site
Coeur D'Alene, Idaho, United States, 83814
United States, Illinois
Pfizer Investigational Site
Alton, Illinois, United States, 62002
Pfizer Investigational Site
Chicago, Illinois, United States, 60637
United States, Indiana
Pfizer Investigational Site
Beech Grove, Indiana, United States, 46107
Pfizer Investigational Site
Indianapolis, Indiana, United States, 46237
Pfizer Investigational Site
Indianapolis, Indiana, United States, 46260
Pfizer Investigational Site
Jeffersonville, Indiana, United States, 47130
United States, Kentucky
Pfizer Investigational Site
Louisville, Kentucky, United States, 40217
Pfizer Investigational Site
Louisville, Kentucky, United States, 40241
Pfizer Investigational Site
Louisville, Kentucky, United States, 40202
Pfizer Investigational Site
Louisville, Kentucky, United States, 40207
Pfizer Investigational Site
Shelbyville, Kentucky, United States, 40065
United States, Louisiana
Pfizer Investigational Site
Baton Rouge, Louisiana, United States, 70809
Pfizer Investigational Site
Baton Rouge, Louisiana, United States, 70806
United States, Maryland
Pfizer Investigational Site
Annapolis, Maryland, United States, 21401
United States, Massachusetts
Pfizer Investigational Site
Burlington, Massachusetts, United States, 01805
Pfizer Investigational Site
Peabody, Massachusetts, United States, 01960
United States, Michigan
Pfizer Investigational Site
Kalamazoo, Michigan, United States, 49007
United States, Mississippi
Pfizer Investigational Site
Columbus, Mississippi, United States, 39705
Pfizer Investigational Site
Corinth, Mississippi, United States, 38834
Pfizer Investigational Site
Southaven, Mississippi, United States, 38671
Pfizer Investigational Site
Tupelo, Mississippi, United States, 38801
United States, Missouri
Pfizer Investigational Site
St. Louis, Missouri, United States, 63136
United States, Montana
Pfizer Investigational Site
Billings, Montana, United States, 59101
United States, Nebraska
Pfizer Investigational Site
Lincoln, Nebraska, United States, 68510
United States, Nevada
Pfizer Investigational Site
Las Vegas, Nevada, United States, 89135
United States, New York
Pfizer Investigational Site
Mineola, New York, United States, 11501
Pfizer Investigational Site
Syracuse, New York, United States, 13210
United States, Ohio
Pfizer Investigational Site
Canton, Ohio, United States, 44718
Pfizer Investigational Site
Columbus, Ohio, United States, 43214
Pfizer Investigational Site
Sylvania, Ohio, United States, 43560
United States, Oregon
Pfizer Investigational Site
Portland, Oregon, United States, 97227-1191
United States, Tennessee
Pfizer Investigational Site
Knoxville, Tennessee, United States, 37920
Pfizer Investigational Site
Knoxville, Tennessee, United States, 37934
Pfizer Investigational Site
Knoxville, Tennessee, United States, 37916
Pfizer Investigational Site
Memphis, Tennessee, United States, 38120
Pfizer Investigational Site
Memphis, Tennessee, United States, 38104
United States, Texas
Pfizer Investigational Site
Austin, Texas, United States, 78705
Pfizer Investigational Site
Austin, Texas, United States, 78745
Pfizer Investigational Site
Austin, Texas, United States, 78758
Pfizer Investigational Site
Austin, Texas, United States, 78759
Pfizer Investigational Site
Dallas, Texas, United States, 75390
Pfizer Investigational Site
Dallas, Texas, United States, 75325-7786
Pfizer Investigational Site
Dallas, Texas, United States, 75325
Pfizer Investigational Site
Round Rock, Texas, United States, 78664
United States, Utah
Pfizer Investigational Site
Salt Lake City, Utah, United States, 84112
United States, Virginia
Pfizer Investigational Site
Lynchburg, Virginia, United States, 24501
United States, Washington
Pfizer Investigational Site
Everett, Washington, United States, 98201
Pfizer Investigational Site
Federal Way, Washington, United States, 98003
Pfizer Investigational Site
Kennewick, Washington, United States, 99336
Pfizer Investigational Site
Lakewood, Washington, United States, 98499
Pfizer Investigational Site
Puyallup, Washington, United States, 98372
Pfizer Investigational Site
Tacoma, Washington, United States, 98405
Argentina
Pfizer Investigational Site
Bahia Blanca, Buenos Aires, Argentina, B8000FJI
Pfizer Investigational Site
La Plata, Buenos Aires, Argentina, B1900AVG
Pfizer Investigational Site
Ciudad Autonoma de Buenos Aires, Argentina, C1426ANZ
Pfizer Investigational Site
Santa Fe, Argentina, 3000
Australia, New South Wales
Pfizer Investigational Site
St. Leonards, New South Wales, Australia, 2065
Pfizer Investigational Site
Wollongong, New South Wales, Australia, 2500
Australia, Victoria
Pfizer Investigational Site
Clayton, Victoria, Australia, 3168
Pfizer Investigational Site
East Bentleigh, Victoria, Australia, 3165
Austria
Pfizer Investigational Site
Salzburg, Austria, A-5020
Pfizer Investigational Site
Wels, Austria, A-4600
Pfizer Investigational Site
Wien, Austria, 1030
Pfizer Investigational Site
Wien, Austria, A-1090
Pfizer Investigational Site
Wien, Austria, 1090
Belgium
Pfizer Investigational Site
Brussel, Belgium, 1090
Pfizer Investigational Site
Bruxelles, Belgium, 1000
Pfizer Investigational Site
Bruxelles, Belgium, 1200
Pfizer Investigational Site
Gent, Belgium, 9000
Pfizer Investigational Site
Leuven, Belgium, 3000
Pfizer Investigational Site
Wilrijk, Belgium, 2610
Canada, Alberta
Pfizer Investigational Site
Edmonton, Alberta, Canada, T6G 1Z2
Canada, British Columbia
Pfizer Investigational Site
Kelowna, British Columbia, Canada, V1Y 5L3
Pfizer Investigational Site
Victoria, British Columbia, Canada, V8R 6V5
Canada, Manitoba
Pfizer Investigational Site
Winnipeg, Manitoba, Canada, R3E 0V9
Pfizer Investigational Site
Winnipeg, Manitoba, Canada, R2H 2A6
Canada, New Brunswick
Pfizer Investigational Site
Moncton, New Brunswick, Canada, E1C 6Z8
Canada, Ontario
Pfizer Investigational Site
Kingston, Ontario, Canada, K7L 2V7
Pfizer Investigational Site
Kingston, Ontario, Canada, K7L 5P9
Pfizer Investigational Site
Oshawa, Ontario, Canada, L1G 2B9
Pfizer Investigational Site
Toronto, Ontario, Canada, M4N 3M5
Canada, Quebec
Pfizer Investigational Site
Montreal, Quebec, Canada, H1T 2M4
Pfizer Investigational Site
Montreal, Quebec, Canada, H4J 1C5
Pfizer Investigational Site
Montreal, Quebec, Canada, H2X 3J4
France
Pfizer Investigational Site
Clichy cedex, France, 92118
Pfizer Investigational Site
La Chaussee Saint Victor, France, 41260
Pfizer Investigational Site
Marseille, France, 13385 CEDEX 5
Pfizer Investigational Site
Montpellier Cedex 02, France, 34298
Pfizer Investigational Site
Paris, France, 75015
Pfizer Investigational Site
PARIS Cedex 13, France, 75651
Pfizer Investigational Site
Pessac Cedex, France, 33600
Pfizer Investigational Site
Rouen, France, 76041
Pfizer Investigational Site
St Herblain Cedex, France, 44805
Germany
Pfizer Investigational Site
Berlin, Germany, 13353
Pfizer Investigational Site
Dresden, Germany, 01307
Pfizer Investigational Site
Essen, Germany, 45136
Pfizer Investigational Site
Greifswald, Germany, 17475
Pfizer Investigational Site
Magdeburg, Germany, 39130
Pfizer Investigational Site
Mannheim, Germany, 68167
Pfizer Investigational Site
Muenchen, Germany, 81377
Pfizer Investigational Site
Oldenburg, Germany, 26133
Pfizer Investigational Site
Ulm, Germany, 89081
Hong Kong
Pfizer Investigational Site
Shatin, NT, Hong Kong
Hungary
Pfizer Investigational Site
Budapest, Hungary, 1097
Pfizer Investigational Site
Budapest, Hungary, 1106
Pfizer Investigational Site
Budapest, Hungary, 1122
Pfizer Investigational Site
Kaposvar, Hungary, 7400
Pfizer Investigational Site
Szentes, Hungary, 6600
Pfizer Investigational Site
Zalaegerszeg, Hungary, 8900
India
Pfizer Investigational Site
Ahmedabad, Gujarat, India, 380 009
Pfizer Investigational Site
Bangalore, Karnataka, India, 560 078
Pfizer Investigational Site
Cochin, Kerala, India, 682 304
Pfizer Investigational Site
Andhra, Pradesh, India, 500 034
Pfizer Investigational Site
Chennai, Tamil Nadu, India, 600035
Ireland
Pfizer Investigational Site
Dublin, Ireland, 4
Pfizer Investigational Site
Dublin 24, Ireland
Italy
Pfizer Investigational Site
Bologna, Italy, 40138
Pfizer Investigational Site
Catania, Italy, 95122
Pfizer Investigational Site
Milano, Italy, 20133
Pfizer Investigational Site
Milano, Italy, 20132
Pfizer Investigational Site
Padova, Italy, 35128
Pfizer Investigational Site
Verona, Italy, 37134
Japan
Pfizer Investigational Site
Nagoya, Aichi, Japan
Pfizer Investigational Site
Chiba-shi, Chiba-ken, Japan
Pfizer Investigational Site
Chiba city, Chiba, Japan
Pfizer Investigational Site
Kashiwa-shi, Chiba, Japan
Pfizer Investigational Site
Fukuoka-shi, Fukuoka-ken, Japan
Pfizer Investigational Site
Yokohama-shi, Kanagawa, Japan
Pfizer Investigational Site
Osaka-shi, Osaka-fu, Japan
Pfizer Investigational Site
Suntougun, Shizuoka, Japan
Pfizer Investigational Site
Chuo-ku, Tokyo, Japan
Korea, Republic of
Pfizer Investigational Site
Seoul, Korea, Republic of, 135-710
Pfizer Investigational Site
Seoul, Korea, Republic of, 138-736
Pfizer Investigational Site
Seoul, Korea, Republic of, 110-744
Pfizer Investigational Site
Seoul, Korea, Republic of, 136-705
Netherlands
Pfizer Investigational Site
Amsterdam, Noord Holland, Netherlands, 1105 AZ
Pfizer Investigational Site
Amsterdam, Netherlands, 1081 HV
Russian Federation
Pfizer Investigational Site
Moscow, Russian Federation, 115478
Pfizer Investigational Site
Moscow, Russian Federation, 129128
Pfizer Investigational Site
Moscow, Russian Federation, 125376
Pfizer Investigational Site
Omsk, Russian Federation, 644013
Pfizer Investigational Site
Sochi, Russian Federation, 354057
Pfizer Investigational Site
St. Petersburg, Russian Federation, 198255
Pfizer Investigational Site
St. Petersburg, Russian Federation, 191104
Singapore
Pfizer Investigational Site
Singapore, Singapore, 16910
Pfizer Investigational Site
Singapore, Singapore, 119074
South Africa
Pfizer Investigational Site
Cape Town, South Africa, 7500
Pfizer Investigational Site
Observatory, South Africa, 7925
Pfizer Investigational Site
Parktown, South Africa, 2193
Pfizer Investigational Site
Port Elizabeth, South Africa, 6001
Pfizer Investigational Site
Pretoria, South Africa, 0181
Pfizer Investigational Site
Sandton, South Africa, 2199
Spain
Pfizer Investigational Site
Palma de Mallorca, Islas Baleares, Spain, 07198
Pfizer Investigational Site
Mostoles, Madrid, Spain, 28935
Pfizer Investigational Site
Pamplona, Navarra, Spain, 31008
Pfizer Investigational Site
Barcelona, Spain, 08036
Pfizer Investigational Site
Barcelona, Spain, 08035
Pfizer Investigational Site
Las Palmas de Gran Canaria, Spain, 35020
Pfizer Investigational Site
Madrid, Spain, 28046
Pfizer Investigational Site
Malaga, Spain, 29010
Pfizer Investigational Site
Santa Cruz de Tenerife, Spain, 38320
Pfizer Investigational Site
Toledo, Spain, 45004
Sweden
Pfizer Investigational Site
Lund, Sweden, 221 85
Pfizer Investigational Site
Uppsala, Sweden, 751 85
Switzerland
Pfizer Investigational Site
Winterthur, Switzerland, 8401
Taiwan
Pfizer Investigational Site
Kuei-Shan Jsoamg, Taoyuan County, Taiwan, 333
Pfizer Investigational Site
Taichung, Taiwan, 404
Pfizer Investigational Site
Taipei, Taiwan, 112
United Kingdom
Pfizer Investigational Site
Whitchurch, Cardiff, United Kingdom, CF14 2TL
Pfizer Investigational Site
Maidstone, Kent, United Kingdom, ME16 9QQ
Pfizer Investigational Site
Leicester, Leicestershire, United Kingdom, LE1 5WW
Pfizer Investigational Site
Withington, Manchester, United Kingdom, M20 4BX
Pfizer Investigational Site
Northwood, Middlesex, United Kingdom, HA6 2RN
Pfizer Investigational Site
Birmingham, United Kingdom, B15 2TA
Pfizer Investigational Site
Birmingham, United Kingdom, B15 2TT
Pfizer Investigational Site
Edinburgh, United Kingdom, EH4 2XU
Pfizer Investigational Site
London, United Kingdom, W12 OHS
Pfizer Investigational Site
London, United Kingdom, EC1A 7BE
Pfizer Investigational Site
Manchester, United Kingdom, M20 4BX
Pfizer Investigational Site
Southhampton, United Kingdom, S016 6YD
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided by Pfizer

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00471146     History of Changes
Other Study ID Numbers: A4061028
Study First Received: May 7, 2007
Results First Received: February 25, 2012
Last Updated: June 14, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
Randomized Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine Plus Placebo For Advanced Pancreatic Cancer.

Additional relevant MeSH terms:
Pancreatic Neoplasms
Carcinoma, Pancreatic Ductal
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Carcinoma, Ductal
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Ductal, Lobular, and Medullary
Gemcitabine
Axitinib
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Radiation-Sensitizing Agents

ClinicalTrials.gov processed this record on October 19, 2014